文献速递自身炎症与 IgG4 相关病

成人Still病生物制剂药物留存率研究

Drug retention rates of biological agents in adult onset Still's disease.
PubMed 文献 · Semin Arthritis Rheum · 2020-12-11

24个月DRR为托珠单抗(TCZ)62.5%、阿那白滞素(ANK)53.1%、TNF抑制剂(TNFi)11.8%;TCZ与ANK相似且均显著高于TNFi,既往生物制剂使用不影响DRR。

要点

  • TCZ与ANK的24个月DRR相似且显著高于TNFi。
  • 既往生物制剂使用未显著影响DRR(HR 0.73,95%CI 0.40-1.31,p=0.288)。
  • 46%的治疗疗程在24个月内停用。

核心结论

  • 在AOSD研究人群中,TCZ与ANK的24个月DRR相似,且均显著高于TNFi的DRR。
  • 既往使用生物制剂未影响DRR。

研究设计与样本

  • 采用Kaplan-Meier法绘制生存曲线,分层log-rank检验比较,计算各bDMARD的24个月DRR及既往bDMARD使用的风险比(HR)。

主要发现

  • ANK使用最多(n=41),其次为TCZ(n=21)和TNFi(n=17)。
  • 所有疗程均联用泼尼松(平均剂量23±18 mg/天),54个疗程(68%)联用csDMARD。
  • 24个月DRR:TCZ 62.5%,ANK 53.1%,TNFi 11.8%。
  • ANK与TCZ的DRR相似(p=0.576),但均显著高于TNFi(p=0.015)。

关键数值与推荐

  • 24个月DRR:TCZ 62.5%,ANK 53.1%,TNFi 11.8%。
  • ANK与TCZ比较p=0.576;ANK/TCZ与TNFi比较p=0.015。
  • 既往生物制剂使用对DRR的HR 0.73(95%CI 0.40-1.31,p=0.288)。

临床怎么用

  • 在AOSD中,TCZ和ANK的24个月药物留存率优于TNFi,既往生物制剂使用不影响后续DRR。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess drug retention rates (DRRs) and reasons for discontinuation of biologic disease-modifying antirheumatic drugs (bDMARDs) in a large monocentric cohort of patients with adult onset Still's disease (AOSD). METHODS: Clinical data of AOSD patients treated with at least one bDMARD and followed up at our Center were retrospectively evaluated. Data about disease duration, number of previous bDMARDs, concomitant treatments, and reasons for therapy discontinuation were collected. Survival curves were examined by the Kaplan-Meier method and compared using a stratified log-rank test. 24-month DRRs were calculated for each bDMARD. Hazard ratio (HR) for previous bDMARD use was evaluated. RESULTS: Forty-two AOSD patients received a total of 79 bDMARD-courses. Anakinra (ANK; n = 41) was the most frequently used bDMARD, followed by tocilizumab (TCZ; n = 21) and Tumor Necrosis Factor inhibitors (TNFi; n = 17). Biologic agents were administered concomitantly with prednisone in all cases (mean dose, 23 ± 18 mg/day) and with csDMARD therapy in 54 (68%) of courses. Thirty-six (46%) treatment courses were discontinued by 24 months. DRRs at 24 months were 62.5% for TCZ, 53.1% for ANK, and 11.8% for TNFi. ANK and TCZ DRRs were similar (p = 0.576), but significantly higher than TNFi (p = 0.015). Previous biologic therapies did not impact DRR (HR 0.73, 95% CI = 0.40 - 1.31, p = 0.288). CONCLUSIONS: In our AOSD study population, 24 months DRRs of TCZ and ANK were similar and significantly higher than the TNFi DRR. Previous use of biologic agents did not affect DRRs.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Campochiaro C, Farina N, Tomelleri A, et al. Drug retention rates of biological agents in adult onset Still's disease. Semin Arthritis Rheum. 2020. PMID: 33340821. doi:10.1016/j.semarthrit.2020.09.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。